• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Unspecified (PubMed=2216456).
  

PubMed=2486618
Kato K., Ikeda H., Akiyama Y., Suda J., Eguchi M., Furukawa T.
Establishment and characterization of human rhabdomyosarcoma cell line (RMS).
Hum. Cell 2:214-215(1989)

PubMed=2216456
Stratton M.R., Moss S., Warren W., Patterson H., Clark J., Fisher C., Fletcher C.D.M., Ball A.B.S., Thomas M., Gusterson B.A., Cooper C.S.
Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene.
Oncogene 5:1297-1301(1990)

PubMed=18082704; DOI=10.1016/j.jpedsurg.2007.08.026
Komuro H., Saihara R., Shinya M., Takita J., Kaneko S., Kaneko M., Hayashi Y.
Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines.
J. Pediatr. Surg. 42:2040-2045(2007)

PubMed=19235922; DOI=10.1002/gcc.20655
Missiaglia E., Selfe J., Hamdi M., Williamson D., Schaaf G., Fang C., Koster J., Summersgill B.M., Messahel B., Versteeg R., Pritchard-Jones K., Kool M., Shipley J.M.
Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.
Genes Chromosomes Cancer 48:455-467(2009)

PubMed=23578105; DOI=10.1111/cas.12173; PMCID=PMC7657110
Nishimura R., Takita J., Sato-Otsubo A., Kato M., Koh K., Hanada R., Tanaka Y., Kato K., Maeda D., Fukayama M., Sanada M., Hayashi Y., Ogawa S.
Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.
Cancer Sci. 104:856-864(2013)

PubMed=23665679; DOI=10.1038/onc.2013.129
Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
Oncogene 33:1877-1889(2014)

PubMed=36768928; DOI=10.3390/ijms24032601; PMCID=PMC9917031
Timpanaro A., Piccand C., Uldry A.-C., Bode P.-K., Dzhumashev D., Sala R., Heller M., Rossler J., Bernasconi M.
Surfaceome profiling of cell lines and patient-derived xenografts confirm FGFR4, NCAM1, CD276, and highlight AGRL2, JAM3, and L1CAM as surface targets for rhabdomyosarcoma.
Int. J. Mol. Sci. 24:2601.1-2601.28(2023)